NCT05239689
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies
Zhejiang University·Early Phase 1·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- AML
- Drug/Device/Intervention
- CD38 CAR T-cells
- Study type
- Interventional
- Intervention type
- biological
Sponsor & location
- Primary sponsor
- Zhejiang University
- Location
- Hangzhou, China
Timeline & enrollment
- Phase
- Early Phase 1
- Start date
- Feb 28, 2022
- End date
- Dec 05, 2024
- Enrollment
- 36 participants
Primary outcome
Dose-limiting toxicity (DLT),Incidence of treatment-emergent adverse events (TEAEs)
Summary
Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of
 CD38-positive Hematological Malignancies
ICD-10 classifications
Acute myeloblastic leukaemia [AML]
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05239689
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05239689 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Zhejiang University and is currently Recruiting. The study focuses on AML. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.